Symbiotec Pharmalab Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹0(0.00%)
Premium (ELP)
Symbiotec Pharmalab Limited's is preparing to launch its Initial Public Offering (IPO) with a substantial issue size of TBD. The offering comprises a fresh issue component of TBD, alongside an Offer for Sale (OFS) component of ₹2030.00 Cr from existing shareholders.
The price band for the IPO has been set at TBD, providing investors with a range to place their bids. The minimum investment lot consists of TBD, making it accessible to both retail and institutional investors.
The subscription window for this public offering opens on TBD and will conclude on TBD. Following the subscription period, the share allotment is scheduled for TBD, with the official listing expected to commence on TBD on the NSE, BSE exchange.
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
The expected premium is based on market buzz and online information. It should not be considered as the actual listing price or valuation. Always refer to the RHP and seek advice from a financial expert before making any investment decisions.
- Strong Global Regulatory Approvals : Approved by US FDA, EU-GMP, and other global bodies, ensuring high credibility and export potential.
- Vertically Integrated Manufacturing : Backward-integrated platform with multi-scale production improves cost efficiency and control.
- R&D and Technology Focus : Continuous investment in research enhances innovation and expands product portfolio.
- High Regulatory Compliance Risk : Pharmaceutical business is highly regulated, and any non-compliance can impact operations.
- Dependence on Key Products : Heavy reliance on steroidal and corticosteroid APIs may limit diversification.
- Capital Intensive Operations : Requires ongoing investment in R&D, facilities, and compliance standards.
- Anil Satwani
- Kashish Satwani
- Sushil Satwani
- Satwani Holdings LLP
Symbiotec Pharmalab Limited
Link Intime India Private Limited